Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.23 USD
0.00 (0.00%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 141 - 160 ( 272 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
July and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
FDA Clinical Hold: Not Game Over but Raises Uncertainty for RG-101''s Clinical Timing and Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Full RG-101/DAA Combo Phase 2 POC SVR12 Results Suggest to Us a 4-Week HCV "Cure" Is Achievable; Reiterate OUTPERFORM and $35 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 6
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
June and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
May and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials: Cash Covers HCV and ATHENA Clinical Catalysts; Reiterating OUTPERFORM but Reducing PT to $35 With Updated Pipeline Assumptions
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-101 / DAA Interim Phase 2 Results Appear Durable - Likely to Hit 12 Week Primary Endpoint in Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 11
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 4
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
New Data from the Phase 2 Combo Study of RG-101 for HCV to Be Presented at EASL; Reiterate OUTPERFORM and $48 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
March and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4:15 Financials: We Project Cash Runway Into Q3:17. Multiple Potential Clinical Catalysts in the Next 3-9 Months; Reiterate OUTPERFORM and $48 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Interim Results Suggest Addition of RG-101 May Reduce Curative HCV Treatment Regimens to 29 Days; Reiterate OUTPERFORM and Raising PT to $48
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 15
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D